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Abstract 
Isolated macrodactyly (OMIM 155500) belongs to a heterogeneous group of 
overgrowth syndromes. It is a congenital anomaly resulting in enlargement of all tissues 
localized to the terminal portions of a limb and caused by somatic mutations in the 
phosphatidylinositol 3-kinase catalytic alpha (PIK3CA, OMIM 171834) gene. Here we report 
a Hungarian girl with macrodactyly and syndactyly. Genetic screening at hotspots in the 
PIK3CA gene identified a mosaic mutation (c.1624G>A, p.Glu542Lys) in the affected tissue, 
but not in the peripheral blood. To date, this somatic mutation has been reported in eight 
patients affected by different forms of segmental overgrowth syndromes. Detailed analysis of 
the Hungarian child and previously reported cases suggests high phenotypic diversity 
associated with the p.Glu542Lys somatic mutation. The identification of the mutation 
provides a novel therapeutic modality for the affected patients: those who carry somatic 
mutations in the PIK3CA gene are potential recipients of a novel “repurposing” approach of 
rapamycin treatment. 
 
Key words 
overgrowth syndromes, macrodactyly and syndactyly, PIK3CA gene, somatic mutation, 
phenotypic diversity  
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Introduction 
Macrodactyly (OMIM 155500) refers to a rare congenital malformation occurring in 
approximately 1 in 100,000 live births and is characterized by an increase in the size of all the 
structures of the limbs, including soft tissues, bones, vessels, nerves and skin (1). It typically 
affects the terminal portions of the limb within a “nerve territory” and the individual 
peripheral nerve is both enlarged and elongated (1). Recently macrodactyly has been added to 
the growing list of overgrowth syndromes caused by somatic mutations of the 
phosphatidylinositol 3-kinase catalytic alpha (PIK3CA, OMIM 171834) gene (1-3).  
Further somatic overgrowth diseases associated with mosaic PIK3CA mutations 
include fibroadipose hyperplasia and non-classifiable conditions characterized by muscular, 
boney and fatty tissue overgrowth, congenital lipomatous overgrowth, vascular 
malformations, epidermal nevi and skeletal abnormalities (CLOVES) syndrome, 
hemihyperplasia multiple lipomatosis, and the brain overgrowth conditions megalencephaly 
capillary malformation and megalencephaly-polymicrogyria-hydrocephalus syndrome 
(MPPH) (2, 4-8). The phenotypic heterogeneity in these syndromes is attributed to the 
location of the cells bearing the mutation and to the proportion of the affected cells in the 
patient’s tissues (9).  
Here we describe a 4-year-old Hungarian patient with isolated macrodactyly and 
syndactyly caused by the c.1624G>A, p.Glu542Lys somatic mutation of the PIK3CA gene. 
We also provide detailed comparison of the clinical symptoms of the Hungarian patient with 
previously reported cases having the same p.Glu542Lys somatic PIK3CA mutation.  
 
Clinical report 
A 4-year-old Hungarian girl was referred to the Department of Medical Genetics 
(University of Szeged, Szeged, HUNGARY) with isolated macrodactyly on the third and 
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fourth fingers of the left hand (Fig. 1a). X-ray imaging proved that the disease is characterized 
not only by the overgrowth of the soft tissues but also by the overgrowth of the bones of the 
affected fingers (Fig. 1b). In addition to macrodactyly, syndactyly was associated with 
concrescence of the fingers and was constrained to the soft tissues of the affected fingers and 
not to the bones (Fig. 1a,b). The macrodactyly and syndactyly of the left hand was present at 
birth and slowly progressed with the growth of the child. On examination, no vascular 
abnormality was present. There was no associated abnormality of the internal organs. Other 
body parts were symmetric and equally developed. The patient's parents were clinically 
unaffected, and they were not aware of any other family members with either macrodactyly or 
syndactyly (Fig. 1c).  
The performed genetic investigation was approved by the Internal Review Board of 
the University of Szeged. The study was conducted according to the Principles of the 
Declaration of Helsinki. After informed consent was obtained from the parents, peripheral 
blood sample and deep surgical excision of the affected left hand were taken in order to 
perform genetic analysis. Genomic DNA was isolated with the QIAamp DNA Mini Kit 
(QIAGEN, Hilden, Germany). Primer sequences were obtained from the UCSC Genome 
Browser. The coding regions and flanking introns of the PIK3CA gene were amplified and 
sequenced with a traditional capillary sequencer (ABI Prism 7000). Since traditional 
sequencing did not identify any putative causative variant of the PIK3CA gene, mutational 
hotspots were screened using an in-house PCR-based restriction fragment assay which has 
been previously described (10) (Cambridge, UK). Examining the region surrounding codon 
542, a PCR product of 180 base pairs in length was amplified and digested with the XbaI 
restriction enzyme for 2 hours at 37°C. The resulting fragments were detected by fluorescent 
read-out using GeneMapper
®
 software with GeneScan LIZ 500 (Life Technologies 
Corporation) as the size standard. A mosaic mutation at codon 542 (c.1624G>A, 
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p.Glu542Lys) was identified in the affected tissue with 4% mutation burden (Fig. 2a). This 
mutation was not present in the genomic DNA sample isolated from the peripheral blood of 
the patient (Fig. 2b). This genetic analysis confirmed that the development of macrodactyly 
and syndactyly of the third and fourth fingers of the left hand are the consequence of the 
mosaicism of the p.Glu542Lys mutation in the PIK3CA gene. 
 
Discussion 
The case reported in this study presented with macrodactyly and syndactyly of the 
third and fourth fingers of the left hand. Genetic investigation identified a somatic missense 
gain-of-function mutation (p.Glu542Lys) of the PIK3CA gene (ClinVar database, 
http://www.ncbi.nlm.nih.gov/clinvar/ accession number: SCV000258982). This mutation 
affects the helical domain of the p110α catalytic subunit of the PI3K protein (11). Functional 
studies have previously shown that this p.Glu542Lys variant caused hyperactivation of AKT, 
a down-stream target of PI3K in the nerve cells of a patient with macrodactyly (1). This 
particular mutation has been reported in eight patients with different forms of segmental 
overgrowth (Table 1) (1-3, 12). 
Patients with somatic p.Glu542Lys mutation of the PIK3CA gene show high 
phenotypic diversity; Kurek et al. (2012), for example, described a female and a male patient 
affected by CLOVES syndrome. In addition to macrodactyly, both patients developed 
lipomatous overgrowth of the trunk and the limbs and vascular anomalies including 
lymphatic, capillary and venous malformations. The affected female patient also had a 
hypoplastic right kidney (2). A subsequent study reported the prenatal diagnosis of CLOVES 
syndrome in a 27-week-old fetus carrying the same somatic mutation of the PIK3CA gene. 
The observed clinical symptoms at birth were asymmetric chest and abdomen, bilateral 
multicystic malformations and asymmetric growth of the left leg with macrodactyly of the left 
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foot and a sandal gap between the first and second toes (3). Rios et al. (2013) reported two 
patients with the same somatic mutation; both were affected by macrodactyly. However, one 
of the patients was also affected by true muscular hemihypertrophy, which was also attributed 
to the presence of the somatic p.Glu542Lys PIK3CA mutation. A subsequent study has also 
reported three further patients with facial infiltrating lipomatosis, which was attributed to the 
presence of the somatic p.Glu542Lys mutation (12). These patients did not exhibit 
macrodactyly.  
The high phenotypic diversity associated with the somatic p.Glu542Lys mutation 
might be explained by the different time points, in which the mutational events occurred 
during embryogenesis. Patients with CLOVES syndrome might have developed the same 
somatic p.Glu542Lys mutation earlier during the embryogenesis than the ones with regional 
overgrowth (macrodactyly or facial infiltrating lipomatosis). 
Genetic analysis has a huge significance for these patients, as once the genetic cause is 
determined, pharmacological intervention could be considered as a therapeutic option. In the 
interim, there are no clinically approved therapies for this condition; however there is a 
theoretical possibility that small molecule inhibitors of the PI3K-AKT-mTOR signaling 
pathway could be effective therapies for these patients (13, 14). Rapamycin (sirolimus) 
indirectly targets PI3K and may also be useful in treating macrodactyly (13, 14). In addition, 
rapamycin has been reported to be effective in isolated cases of allied conditions and may 
promote a breakthrough in the treatment of macrodactyly and overgrowth syndromes. 
However, long-term safety data of this treatment in PIK3CA-related overgrowth is currently 
lacking and, thus, indicates the need for formal clinical trials to evaluate safety and efficacy. 
In light of the current situation, detailed genetic investigation and publication of these isolated 
cases is essential. 
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Figure Legends 
 
Figure 1. Macrodactyly and syndactyly in a 4-year-old girl. (a) Clinical features and (b) 
bone radiographs of the patient. (c) The patient's family is clinically asymptomatic. 
 
Figure 2. Genetic investigation of the Hungarian patient with macrodactyly and 
syndactyly. (a) DNA was extracted from the affected left hand and subjected to a PCR 
restriction assay, which identified the PIK3CA p.Glu542Lys mutation at 4% mutation burden. 
(b) In DNA extracted from the peripheral blood, the peak indicating the presence of the 
mutation was absent in the digested PCR product, indicating the mosaicism of the mutation.  
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Table 1. Summary of the phenotypic diversity of the patients with somatic p.Glu542Lys 
PIK3CA mutation. 
Patients 
Index 
Patient 
Patient 2 Patient 3 Patient 4 Patient 5 Patient 6 Patient 7 Patient 8 Patient 9 
Clinical 
diagnosis 
Macro-
dactyly, 
Syndactyly 
Macro-
dactyly 
Macro-
dactyly, 
Muscular 
hemi-
hypert-
rophy 
Facial 
infiltrating 
lipo-
matosis 
Facial 
infiltrating 
lipo-
matosis 
Facial 
infiltrating 
lipo-
matosis 
CLOVES 
syndrome 
CLOVES 
syndrome 
CLOVES 
syndrome 
Publication This report 
Rios et al. 
2013 
Rios et al. 
2013 
Maclellan 
et al. 2014 
Maclellan 
et al. 2014 
Maclellan 
et al. 2014 
Kurek et al. 
2012 
Kurek et al. 
2012 
Emrick et 
al. 2014 
Percentage 
(%) of 
somatic 
mosaicism 
4 NR NR 23 30 16-18 8 6-13 38 
Lipomatous overgrowth  
Face NR NR NR + + + NR NR NR 
Trunk NR NR NR NR NR NR + + + 
Limb(s) + + + NR NR NR + + + 
Vascular anomalies  
Lymphatic 
malformati
on 
NR NR NR NR NR NR  +  +   +  
Capillary 
malformati
on 
NR NR NR NR NR NR  + +  +  
Venous 
malformati
on 
NR NR NR NR NR NR  +  +  + 
Musculoskeletal  
Macrodacty
ly 
+ +  +  NR NR NR  +   + + 
Limb 
asymmetry 
NR NR NR NR NR NR +   +    
Scoliosis NR NR NR NR NR NR  +      
True 
muscular 
hemihypertr
ophy 
NR NR +  NR NR NR NR NR NR 
Other 
findings 
NR NR NR NR NR NR 
Hypo-plastic 
right kidney 
NR 
Epidermal 
nevi  
NR=not reported 
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The report is generally well written and interesting. As a minor comment, I suggest to change 
the nomenclature of the mutation according to HGVS. On page 6, line 7, I would prefer a 
different sentence structure: "… different time points of the mutational events during 
embryogenesis." 
Reply: Thank you very much for your comments. The nomenclature of the mutation has 
been corrected according to the recommendation of HGVS. On page 6, line 7, the 
structure of the sentence has been changed from „… different time points of the 
mutational events during embryogenesis." to „… different time points, in which the 
mutational events occurred during embryogenesis.” 
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